Zobrazeno 1 - 10
of 363
pro vyhledávání: ''
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose When only the TNM classification is used to predict survival in gastric cancer (GC) patients, the impact of the degree of lymphadenectomy on the prognosis is neglected. This study aimed to establish a more effective nomogram based on the log
Autor:
Kyu-Tae Han, Jongwha Chang, Dong-Woo Choi, Seungju Kim, Dong Jun Kim, Yoon-Jung Chang, Sun Jung Kim
Publikováno v:
BMC Cancer. 22
Background Although survival based outcomes of lung cancer patients have been well developed, institutional transition of cancer care, that is, when patients transfer from primary visiting hospitals to other hospitals, and mortality have not yet been
Autor:
Toshiki Ikawa, Ryu Ishihara, Katsunori Matsueda, Koji Konishi, Sachiko Yamamoto, Masahiro Morimoto, Naoyuki Kanayama, Teruki Teshima
Publikováno v:
BMC Cancer. 22
Background The optimal radiation dose for treating non-metastatic superficial esophageal squamous cell carcinoma is unknown. In this retrospective observational study, we investigated the influence of radiation dose and pretreatment endoscopic predic
Autor:
Renata Ferrarotto, Erich M. Sturgis, Jack Phan, Baher Elgohari, Houda Bahig, Sweet Ping Ng, Faye M. Johnson, David I. Rosenthal, Clifton D. Fuller, G. Brandon Gunn, Steven J. Frank, Amit Jethanandani, Adam S. Garden
Publikováno v:
British Journal of Cancer
Background This study aimed to evaluate the prognostic value of pre-treatment NLR in patients with oropharyngeal cancer. Methods Patients who completed definitive radiotherapy (RT) for oropharyngeal cancer and had blood counts taken pre-RT from 2002
Autor:
Lorenzo Fontanelli, Romano Danesi, Federico Cucchiara, Luca Galli, Marzia Del Re, Federico Paolieri, Francesco Bloise, Andrea Sbrana, Chiara Mercinelli, Stefania Crucitta, Enrico Sammarco
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:527-533
Abiraterone became a standard hormonal therapy for patients with metastatic castration-resistance prostate cancer (mCRPC). However, patients may experience primary resistance to treatment. To date, few predictive biomarkers of efficacy have been iden
Autor:
Céline Forster, Thorsten Krueger, Etienne Abdelnour-Berchtold, Matthieu Zellweger, Michel Gonzalez, Amaya Ojanguren, Sara Federici, Jean Yannis Perentes
Publikováno v:
Clinical & experimental metastasis, vol. 37, no. 6, pp. 675-682
Clinical & Experimental Metastasis
Clinical & Experimental Metastasis
Recurrence after pulmonary metastasectomy (PM) is frequent, but it is unclear to whom repeated pulmonary metastasectomy (RPM) offers highest benefits. Retrospective analysis of oncological and post-operative outcomes of consecutive patients who under
Autor:
Ramadhan Karsono, Samuel J. Haryono, Bambang Karsono, Wirsma Arif Harahap, Yulia Pratiwi, Teguh Aryandono
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Background The ESR1 gene encodes Estrogen Receptor alpha (ERα), which plays a role in the tumourigenesis of breast cancer. A single nucleotide polymorphism (SNP) in intron 1 of this gene called ESR1 PvuII (rs2234693) has been reported to increase th
Autor:
Tadanobu Shimura, Masaki Ohi, Shozo Ide, Yusuke Omura, Yukina Kusunoki, Yoshinaga Okugawa, Hiromi Yasuda, Chengzeng Yin, Junichiro Hiro, Masato Kusunoki, Tsunehiko Shigemori, Kurando Kusunoki, Yuji Toiyama, Hiroyuki Fujikawa
Publikováno v:
Cancer Immunology, Immunotherapy. 69:2533-2546
Programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) play a pivotal role in cancer immunotherapy. Each of these molecules has a membrane-bound receptor form (mPD-L1/mCTLA-4) and a soluble form (sPD-L1/sCTLA-
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:2231-2239
Adjuvant chemotherapy could improve the prognosis of stage II–III non-small cell lung cancer (NSCLC). However, its influences on stage IB were controversial. The purpose of this study was to investigate whether patients with stage IB NSCLC could be
Autor:
F. Haertner, R Schwab, Katrin Almstedt, Martina Schmidt, Anne-Sophie Heimes, Antje Lebrecht, W. Brenner, G.-M. Makris, S. Krajnak, C. Schnatz, Annette Hasenburg, Marco Johannes Battista
Publikováno v:
Breast Cancer Research and Treatment
Purpose There is growing interest in low-dose metronomic chemotherapy (LDMC) in metastatic breast cancer (MBC). In this retrospective case–control analysis, we compared the efficacy of LDMC and conventional chemotherapy (CCT) in MBC. Methods Each L